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ABSTRACT 
Transdermal drug delivery offers numerous advantages over the conventional routs of administration; however, poor permeation of most drug 
across the skin barrier constitutes a major limitation of this rout. 
Objective: The possibility of utilizing azelaic acid as penetration enhancer was investigated. And then development of a new transdermal 
controlled-release device using of non-medicated and lidocaine transdermal patches and then testing the feasibility of loading fentanyl patch.  
Methods: DSC, FTIR, X-ray diffraction analysis and skin permeability measurements were done for both skin sample untreated and treated with 
azelaic acid to prove the possibility of utilizing it as permeation enhancer.  
Multilayered lidocaine transdermal patches were prepared by solvent/evaporation casting technique using Eudragit
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® E100 as transdermal 
adhesive polymer, and ethyl vinyl acetate as impermeable backing layer. The flexibility of films required for a good compliance and optimum 
transdermal adhesion of the Eudragit E films was achieved by employing triethyl citrate or dibutylphthalate at concentration of 25% (w/w) of 
polymer. A physicochemical interaction between azelaic acid and Eudragit E100 (cationic polymer) has been evaluated using FTIR and DSC. 
Lidocaine as well as fentanyl bilayerd transdermal patches containing triethylcitrate at concentration of 25% (w/w) of Eudragit E100 with and 
without azelaic acid were selected for further permeation studies 
Results: The obtained results indicated that fluorescien permeation through epidermal human skin treated with overnight exposure to saturated 
aqueous solution of azelaic acid was increased by 8.6 folds while, its permeation through rat skin was increased by 10.89 folds. Additional analysis 
by FTIR, X-ray diffraction, SEM, and DSC showed that azelaic acid disrupted stratum corneum lipid, which supported its action as promising 
penetration enhancer.Plasticizers as triethyl citrate or dibutylphthalate at concentration of 25% (w/w) of polymer reduced Tg of Eudragit E100 
polymer to about 15.50C and 26.20C respectively. A physicochemical interaction between azelaic acid and Eudragit E100 was proven by FTIR study 
which indicated the present of ionic bonding between them, while DSC showed that azelaic acid may act as non-traditional plasticizer through its 
reduction in Tg by 7.30 C.The results of permeation studies indicated that the presence of azelaic acid was significantly increased (P < 0.05) the drug 
flux as the concentration of azelaic acid increased. As well as; fentanyl transdermal permeability studies revealed similar behavior to lidocaine as 
drug flux increased by 4.82 folds at AZ concentration of 2mg/cm2
 
INTRODUCTION 
The barrier property of stratum corneum is essential to its 
protective role but hinder transdermal drug delivery. Penetration 
enhancers can increase the stratum corneum's permeability and aid 
the transdermal delivery of drugs by altering its structural 
organization of lipids [1]. Azelaic acid is a naturally occurring 
saturated dicarboxylic acid produced by ayeast that lives on normal 
skin, modifies epidermal keratinisation, and has antibacterial 
properties against both aerobic and anaerobic bacteria, and 
possesses anti-inflammatory activity [2].
.  
Conclusion: the overall obtained data revealed the feasibility of preparing a controlled release fentanyl transdermal patches containing azelaic acid 
as penetration enhancer.  
Keywords: Azelaic acid, Permeation enhancer, Fentanyl and Transdermal patches. 
  
Physicochemical parameters of drugs as well as their permeation 
constants are important for determining the best drug candidates 
for transdermal delivery [3]. 
Since fentanyl, synthetic piperidine, is a very expensive controlled 
drug and can be available for research only with limited quantity, 
and under certain specification and regulation of the Ministry of 
Health, lidocaine is used as a model drug for the whole study to 
select the best condition for preparing bilayer transdermal patch 
using azelaic acid as penetration enhancer. Then the feasibility of 
loading fentanyl in the developed patch was investigated. Both of 
them had approximately the same properties for passive adhesive 
transdermal patch as: non-ionic, low molecular weight (336.5 for 
fentanyl and 234 for lidocaine), and log P in range 1-3 (2.8 for 
fentanyl and 2.5 for lidocaine ). In addition they are structurally 
related. 
Aim of the Study is to investigate AZ as transdermal penetration 
enhancer. And then development of a new transdermal controlled-
release device using of non-medicated and lidocaine transdermal 
patches and then testing the feasibility of loading fentanyl in the 
developed model patch as well as evaluation of its physicochemical 
properties. 
MATERIALS AND METHODS 
Materials 
Lidocaine base, fentanyl citrate, and azelaic acid(AMP, Jordan). 
Eudragit E 100(Röhm, GmbH,Weiterstdt, Germany) Ethylene vinyl 
acetate copolymer 40 wt% vinyl acetate stabilized and hexane HPLC 
grade(Acros, New Jersey-USA), Triethyl citrate(Sigma- Aldrich, 
England), Dibutyl phthalate(Sharlau, Barcelona- Spain), Trypsin 
enzyme from hog pancreas and Fl Flouresceine(Fluka 
Biochemik,GmbH, Germany), KBr(Merk, Germany) Acetonitrile 
HPLC grade, dichlormethane HPLC grade, sodium hydroxide, and 
ethanol absolute-analytical grade(Sharlau, Barcelona- Spain). 
Human skin ( King Abdulla Hospital, Irbid – Jordan) and Albino 
dorsal rat skin (Animal House at Jordan University of Science and 
Technology). All other reagents were of an analytical grade. 
The daily dose of drug that can be 
delivered from a transdermal patch is 5-10 mg, effectively limiting 
this route of administration to potent drugs [4]. 
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Due to the limited sources of human skin (female skin from 
abdominal surgery), rat skin (dorsal area of albino male rats’ weight 
350±20g) was used in some parts of this study. Epidermis was 
prepared using a heat separation method [5], full thickness of 
human skin pieces were incubated for 90 seconds in hot water (60 
0C), and anatomical forceps were used to peel off the epidermis 
carefully, while stratum corneum isolation was done by placing the skin 
pieces were placed in a petri dish, soaked in 1% trypsin in phosphate 
buffer saline (PBS) pH 7.4 and incubated for 24 hours at 320 C [6]. This 
step was repeated with fresh trypsin solution until the transparent 
stratum corneum was separated and floated over the solution [6].  
Investigation of azelaic acid as penetration enhancer 
Treated human SC samples were prepared by soaking several small 
pieces of SC in saturated aqueous solution of AZ (0.24mg %, w/v) for 
24 hours at room temperature and then washed them with PBS, 
while control human SC samples were prepared by soaking them in 
distilled water. The SC samples were dried under vacuum at 21± 1 
0C (650 mm of Hg) and stored in desiccators to remove traces of 
solvent [7-9].  
Differential scanning calorimeter 
Thermal analysis was carried out for both control and treated 
human SC by sealed SC samples within an aluminium pans and 
heating samples from 0 0C to 120 0C at rate of 10 0C / minute.  
Fourier transform infra red spectroscopy 
A special attention was focused on characterizing the occurrence of 
peaks near 2850 cm-1, 2920 cm-1, and 1650 cm-1 which were due to 
symmetric, asymmetric C-H and C-O stretching frequencies 
respectively[10].  
X-ray diffraction 
The peak that caused by scattering of crystalline cholesterol, which 
is primary component of SC lipid was measured using X-ray 
diffractometer for both control and treated SC samples to study any 
changes in the order of the dominant component of SC lipid bilayer 
structure that caused by AZ [11-12].  
Skin permeability measurement 
Both human epidermis and whole rat skin were used. Before 
measuring skin permeability, epidermal human skin, or whole rat 
skin, was pretreated with AZ by placing them in a vertical, glass 
Franz diffusion cell apparatus with 1.76cm2 exposed skin surface 
area, the receiver chamber was filled with PBS pH 7.4 and the donor 
chamber was filled with 1ml saturated aqueous of AZ. After 12-hr 
exposure to saturate aqueous of AZ at room temperature, the Franz 
cell was transferred to heater/stirrer at 32 0C for 3hrs [13] 
Bi-layered transdermal patches 1-6 (table 1) were prepared by the 
casting / solvent evaporation technique from plasticizer- containing 
polymer solution. After preparing the dried backing layer, and the 
medicated transdermal solution, the plasticized drug / polymer 
solution was poured onto the dried backing layer and dried at room 
temperature overnight. After drying, the dried bilaminated films 
were peeled from glass dish and cut in to circular shape of smaller 
size for further studies[16]. Then the films were stored at 20 ±1
After this 
pretreatment, the receiver chamber was emptied and filled with 
fresh PBS pH7.4 and the donor chamber was emptied and filled with 
1ml of 1mM fluorescein in PBS pH 7.4. Samples were taken at 
different interval of times for 5hr and analyzed 
spectrophotometrically to determine the permeability [14]. 
Preparation of the backing film backing 
Backing layer was prepared by dissolving 3g of EVA in 100 ml 
dichloromethane. Then casting into glass petri dishes with a 
diameter of 5.0 cm and drying at room temperature, for about five 
hours to attain complete dryness [15].  
Preparation of transdermal patche  
0C in 
a desiccator containing saturated solution of sodium dichromate (Na 
2 Cr2 O 7) for at least 2 days before testing. 
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Characterization of the films 
Physical characterization  
The thickness of the patches was measure by using a micrometer, 
weight variation by individual weighing 10 randomly selected 
patches [17], and morphology of transdermal film was observed 
under a scanning electron microscope.  
Differential scanning calorimetric analysis 
Samples of 3-5 mg were placed in crimped aluminium pans. Thermal 
analysis was performed, using an empty crimped pan as a reference, at a 
scan rate of 10°C per min from 20 to 300°C under nitrogen purge at a 
constant flow rate of 20 ml/min.[18]. A glass transition temperature (Tg) 
of the films and the effect of AZ content and plasticizers on Tg were 
determined using the cooling system of the DSC. Thermal analysis was 
performed at multi-step runs as follow: the sample was heated at a rate 
of 20 0C /min to 100 0C (holds there for 5 minutes), quench cool the 
sample, and finally DSC run was carried at a rate of 10 0C /min from -50 
0C to 1000C [19]. Triplicate samples were tested for each formulation. 
Fourier transform infrared analysis 
FTIR spectra of azelaic acid and Eudragit E, as well as their films, 
were measured. Solid samples were prepared as KBr discs. 
Method of lidocaine analysis in aqueous samples 
High performance liquid chromatography (HPLC) analytical method 
was used for the analysis of lidocaine [20] using reverse phase 
column, 15 cm in length and 4.6 mm in diameter. The mobile phase 
acetate buffer pH of 3.4: acetonitrile(4:1). The operating conditions 
included mobile phase flow rate of 1.5 ml/min, volume of injection 
was 30 µl, and detection was carried out at 254 nm. The analysis 
was conducted under ambient temperature.  
Evaluation of in vitro permeability of lidocaine 
In vitro permeation studies for patch no.4 and patch no.6 were 
conducted at 32 ± 1o
In order to compare the effect of AZ concentration on the 
permeation of lidocaine, patches with different concentrations of 
azelaic acid (2, 3, 4, and 5 mg/cm 
C.. Rat skin membrane was used. For comparison, 
the permeability of a controlled solution was studied using the same 
above set up except that a controlled solution composed of 3.5mg of drug 
in 2 ml of PBS was added to the donor cell.  
Evaluation of lidocaine permeation using different amount of az 
2) were prepared. 
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Preparation of fentanyl patches 
Two different types of patches were prepared. Patch A without 
azelaic acid and patch B with azelaic acid as penetration enhancer 
(table 2). 
Table 2: Formulas of (1.76cm2
Formula 
) bilayer fentanyl patches 
First layer Second layer 
patch A EVA 56 mg Eudragit E100 
14 mg TEC 







56 mg Eudragit E100 
3.52 mg AZ 
14 mg TEC 
0.88 mg fentanyl 
  
Evaluation of in vitro Fentanyl Permeation 
For solution permeability study, a control solution composed of 1.0 
mg fentanyl in 2 ml PBS was used and the receptor medium 
consisted of PBS pH 7.4 [21].  
RESULTS AND DISCUSSION 
Investigation of azelaic acid as penetration enhancer 
The DSC thermogram of human SC treated with azelaic acid indicated 
that the first and second transition temperatures(first one at 
approximately 73°C which is assigned to lipid structure transformation 
nd the second one at approximately 92 °C which is assigned to a protein-
associated lipid transition from gel to liquid form) were decreased by 9.1 
and 12 °C, respectively, relative to untreated skin, as illustrated in figure 
1 which is indicative of increased lipid fluidity [22].  
 
Fig. 1: Changes of two characteristic transition midpoint 
temperatures 
 
FTIR: It appears from figure2 that the treatment of skin with AZ raised 
the stretching frequency of asymmetric (CH2) by 2.34cm-1, asymmetric 
(CH2) by 1.11 cm-1, and (CO) by 2.31 cm-1 relative to untreated human 
skin. These data indicate that AZ significantly increased (p < 0.05) 
stratum corneum lipid chain disorder and fluidity as reported [23]. 
Although, these wavenumber shifts are relatively small, they are consistent 
in magnitude with pervious studies of chemical enhancers [24].  
 
 
Fig. 2: FTIR spectra of human SC. (A) Control and (B) Treated 
 
X-ray Diffraction 
Figure (3) represents X-ray diffraction of control and treated human 
SC with AZ. The reduction in the peak intensity associated with 
crystalline form of SC indicated that the AZ reduces lipid bilayer 































































































































Fig. 3: X-ray diffraction of human sc, a( control) and b: (treated) 
 
Effect of Azelaic Acid on Skin Permeability 
The steady state fluxes were calculated from the slope of 
penetration profiles (figure 4), the flux of fluorescein through 
treated human SC skin with AZ was found to be 1.3µg/cm2..hr., while 
flux through untreated skin was 0.15 µg/cm2..hr., so the 
enhancement ratio is 8.6, while for rat skin equals to 10.89(figure 5). 
It appears that AZ significantly (P < 0.05) increased fluorescein 
permeability through human and rat skin but rat skin is often more 
permeable as reported [26].  
 
Fig. 4: Cumulative amount of fluorescein permeated at pH 7.4 




Fig. 5: Cumulative amount of fluorescein permeated at pH 7.4 
and temperature of 32 o
Low standard deviation (table 3) values in the film weight and 
thickness measurements ensured uniformity of thickness in each 
C through:AControl rat skin,B Treated 
rat skin with AZ. (Data expressed as mean ± SD) 
 
Physical characterization of lidocaine patches  
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film indicated that the method of casting solvent technique gives 
reproducible results with regard to film thickness.  












72 +  0.50 
105  +  1.26 
0.40  +  0.01 
0.60  +  0.01 
Lidocaine (2 mg/cm2 74.70  +  0.53 




0.41  +  0.01 
0.61  +  0.01 
 
Morphological analysis 
A smooth, compact surface, clear, and colourless film was noted as 
shown in figure (6). This result agrees with the specification of 
Eudragit E 100 polymer to form a clear and transparent film and 
indicates a good distribution of drug within a polymer [27].  
 
 
Fig. 6: Scanning electron microscope of Eudrgit E 100 
transdermal patch. 
 
Eudragit E100 produces transparent film but it is extremely brittle; 
therefore, two types of plasticizers including TEC and DBP were 
used to determine their influence on the flexibility of Eudragit E 100 
films. Figure (7) shows the effect of TEC on Tg of Eudragit E100, 
Eudragit E100 film had Tg of 39.79 oC, while 10%, 25%, and 30% 
(w/w) polymer content of TEC had Tg of 29.5 oC, 15.5 oC, and 14.9 oC 
respectively. On the other hand, figure (8) illustrated the effect of 
DBP on Tg, 10%, 25%, and 30% (w/w) polymer content of DBP had 
Tg of 31oC, 26.2 oC, and 25.1 oC respectively. The results indicated 
that both TEC and DBP can reduce Tg of polymer to about room 
temperature.  
 
Fig. 7: Effect of triethylcitrate plasticizer concentration on the 
DSC thermogram of Eudragit E film. 
 
A new broad endothermic peak appeared at 121.5 oC (figure 9) may 
be formed due to the possible interaction between cationic Eudragit 
E100 polymer and AZ to form a new complex. Further elucidation of 
the nature of this interaction will be latter conducted using FTIR. 
 
Fig. 8: Effect of dibutylphthalate concentration on the DSC 
thermogram of Eudragit E film. 
 
 
Fig. 9: DSC thermogram A(azelaic acid powder), B Eudrgit E 
film, and C(Eudrgit E- azelaic acid film) 
 
Fourier transform infrared analysis 
Figure (10) represents FTIR spectra of the Eudragit E100-AZ film. A 
strong band appears at 1557 cm-1 which might be assigned to the 
absorption band of carboxylate group that forms the ionic bonds 
with protonated dimethylaminoethyl groups of Eudragit E100.  
On the other hand, a significant peak broading at approximately 
2497 cm-1, might be assigned to the polymer salt absorption band 
which was brought about by the interaction of the 
dimethylaminoethyl groups of Eudragit E100 with the carboxyl 
group of AZ. In addition, the ratio of the bands at 2772 and 2822 cm-
1 significantly changed. This indicates a difference in the amount of 
protonated and non- protonated dimethylaminoethyl groups. 




Fig. 10: FTIR spectra of Eudragit E100-azelaic acid film 
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Evaluation of In vitro Permeability of Lidocaine  
The effect of different concentration of azelaic acid on permeation 
rate of lidocaine transdermal patch (2mg/ cm2) through rat skin was 
investigated to identify optimum concentration and to compare its 
effect with the control. Figure (11) illustrates the permeation profile 
of lidocaine from patches containing different concentrations of 
azelaic acid,( 0, 2, 3, 4, and 5mg/ cm2) as a donor.  
Enhancement ratios (ER) are equal to 2.55, 3.48, 3.77, and 4.0 for 
patches containing AZ at concentration of 2, 3, 4, and 5 mg/ cm2 
respectively. The results indicate that ER was increased significantly 
(P<0.05) as the concentration of AZ increased in the bi-layer 
transdermal patch up to 4.0 folds at 5 mg/ cm2 of AZ. 
Based on the overall in vitro lidocaine release and its skin 
permeability results, the component of bi-layer transdermal patch 4 



































selected as the best formulas for loading fentanyl, also its 
permeation study was done for further supporting the hypothesis 
states that AZ is a promising penetration enhancer in transdermal 
fentanyl drug delivery system.  
 
 
Fig. 11: Cumulative amount of lidocaine (2mg/ cm2) permeated 
from bilayer patch6 containing different concentration of AZ as 
a donor at 32 o
Evaluation of in vitro Permeability of Fentanyl:  
C. Data expressed as mean ± SD (n=3) 
Sink condition was assured in the receiving solution of Franz cell. 
Fentanyl solubility in PBS pH 7.4 at 25 0
Figure (12) illustrates the permeation profile of fentanyl from PBS 
pH7.4 containing 1mg / 2 ml fentanyl as a control solution, patch A, 
and patch B through rat skin. An average flux of 0.563 µg/cm 
C was reported to be 9.8 
mg/ml [28]. Therefore a volume of 15 ml is more than enough to 
solubilize ten times its solubility.  
2.hr, Q 
24 of  7.5 µg, and T lag of 3.2 hr were obtained from control solution, 
while the average diffusion parameters values for fentanyl from 
patch A were; flux of 0.399 µg/cm 2.hr, Q 24 of  5.5 µg, and T lag of 3.7 
hr (table 4). It can be inferred from the data that flux of fentanyl 
from PBS pH 7.4 was significant higher as compared to fentanyl in 
bi-layer transdermal formulation due to its hydration effects on skin 
[29]. On the other hand, inspection of the permeation parameters of 
fentanyl from patch B (table 5) illustrates that fentanyl flux is of 
1.924µg/cm 2.hr, Q 24 is of 26.1 µg, and T lag
 
 is of 1.2 hr. It can be 
concluded that the presence of AZ in the formulation of fentanyl bi-
layer transdermal patch significantly (P<0.05) increased drug flux 



































Fig. 12: Cumulative amount of fentanyl permeated from control 
PBS pH 7.4 (1.0 mg /2ml), patch A, and patch B as donors at 32 
o
Donor 
C. Data expressed as mean ± SD (n=3) 
 







Cumulative amount at 24hr (µg) 
 -3 
Eenhancement factor 
PBS(pH7.4) 3.2(0.09) 0.563(0.04) 1.126(0.06) 7.5(0.53) - 
Patch A 3.7(0.18) 0.399(0.03) 0.798(0.02) 5.5 (0.2) 1.0 
Patch B 1.2(0.04) 1.924(0.02) 3.848(0.12) 26.1(1.9) 4.82 
 
CONCLUSION 
The present study demonstrates that the azelaic acid confirm as a 
promising skin permeation enhancer since it significantly increased 
the permeation of skin to fluoresciene, lidocaine, and fentanyl. 
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